Combination of Tislelizumab, BACE, and Systemic Chemotherapy for NSCLC

Overview

This study evaluates the efficacy and safety of a sequential treatment strategy combining tislelizumab, bronchial arterial chemoembolization (BACE), and systemic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and bulky tumors.

Background

Bulky tumors in advanced NSCLC present significant treatment challenges, often leading to poorer outcomes. The integration of BACE with immunotherapy has emerged as a potential strategy to enhance treatment efficacy. Understanding the effectiveness of this combination in patients with large tumors is crucial for optimizing therapeutic approaches in this population.

Data Highlights

Key Findings

• Group A showed a significantly higher ORR compared to Group B (79.41% vs 44.12%, p = 0.006).
• Median PFS was longer in Group A than in Group B (12.47 months vs 7.73 months, p = 0.024).
• No significant difference in median OS was observed between the two groups (20.73 months vs 19.63 months, p = 0.071).
• Sequential treatment strategy and tumor diameter were identified as independent favorable predictors of PFS.
• Common grade 3 or higher treatment-related adverse events included neutropenia, anemia, and thrombocytopenia.
• BACE-related adverse events were generally mild, with chest pain and transient cough reported.

Clinical Implications

The findings provide data on the efficacy and safety of combining tislelizumab with BACE and systemic chemotherapy in patients with bulky NSCLC tumors.

Conclusion

The sequential treatment strategy combining tislelizumab, BACE, and systemic chemotherapy was associated with a higher objective response rate and improved progression-free survival in patients with bulky tumors in advanced NSCLC.

Related Resources & Content

1. The ASCO Post, 2026 -- Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
2. The ASCO Post, 2025 -- First-Line Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
3. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0 | Journal of Clinical Oncology
4. Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial) - PubMed
5. The ASCO Post — First-Line Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
6. The ASCO Post — Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
7. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0 | Journal of Clinical Oncology
8. Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial) - PubMed
9. Safety and Effectiveness of Drug-Eluting Embolic Bronchial Arterial Chemoembolization for Lung Cancer: A Systematic Review and Meta-Analysis - PubMed